Functional Genomic Analysis of a RUNX3 Polymorphism Associated With Ankylosing Spondylitis.


Journal

Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795

Informations de publication

Date de publication:
06 2021
Historique:
revised: 28 09 2020
received: 28 02 2020
accepted: 15 12 2020
pubmed: 29 12 2020
medline: 13 8 2021
entrez: 28 12 2020
Statut: ppublish

Résumé

To investigate the functional consequences of the single-nucleotide polymorphism rs4648889 in a putative enhancer upstream of the RUNX3 promoter associated with susceptibility to ankylosing spondylitis (AS). Using nuclear extracts from Jurkat cells and primary human CD8+ T cells, the effects of rs4648889 on allele-specific transcription factor (TF) binding were investigated by DNA pull-down assay and quantitative mass spectrometry (qMS), with validation by electrophoretic mobility shift assay (EMSA), Western blotting of the pulled-down eluates, and chromatin immunoprecipitation (ChIP)-quantitative polymerase chain reaction (qPCR) analysis. Further functional effects were tested by small interfering RNA knockdown of the gene for interferon regulatory factor 5 (IRF5), followed by reverse transcription-qPCR (RT-qPCR) and enzyme-linked immunosorbent assay (ELISA) to measure the levels of IFNγ messenger RNA (mRNA) and protein, respectively. In nuclear extracts from CD8+ T cells, results of qMS showed that relative TF binding to the AS-risk A allele of rs4648889 was increased 3.7-fold (P < 0.03) for Ikaros family zinc-finger protein 3 (IKZF3; Aiolos) and components of the NuRD complex, including chromodomain helicase DNA binding protein 4 (CHD4) (3.6-fold increase; P < 0.05) and retinoblastoma binding protein 4 (RBBP4) (4.1-fold increase; P < 0.03). In contrast, IRF5 bound significantly more to the AS-protective G allele compared to the AS-risk A allele (fold change 8.2; P = 0.003). Validation with Western blotting, EMSA, and ChIP-qPCR confirmed the differential allelic binding of IKZF3, CHD4, RBBP4, and IRF5. Silencing of IRF5 in CD8+ T cells increased the levels of IFNγ mRNA as measured by RT-qPCR (P = 0.03) and IFNγ protein as measured by ELISA (P = 0.02). These findings suggest that the association of rs4648889 with AS reflects allele-specific binding of this enhancer-like region to certain TFs, including IRF5, IKZF3, and members of the NuRD complex. IRF5 may have crucial influences on the functions of CD8+ lymphocytes, a finding that could reveal new therapeutic targets for the management of AS.

Identifiants

pubmed: 33369221
doi: 10.1002/art.41628
pmc: PMC8251554
doi:

Substances chimiques

CHD4 protein, human 0
Core Binding Factor Alpha 3 Subunit 0
IFNG protein, human 0
IKZF3 protein, human 0
IRF5 protein, human 0
Interferon Regulatory Factors 0
RBBP4 protein, human 0
RNA, Messenger 0
RNA, Small Interfering 0
Retinoblastoma-Binding Protein 4 0
Runx3 protein, human 0
Transcription Factors 0
Ikaros Transcription Factor 148971-36-2
Interferon-gamma 82115-62-6
Mi-2 Nucleosome Remodeling and Deacetylase Complex EC 3.5.1.98

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

980-990

Subventions

Organisme : Versus Arthritis
ID : 20402
Pays : United Kingdom
Organisme : Versus Arthritis
ID : 21428
Pays : United Kingdom
Organisme : Versus Arthritis
ID : 20796
Pays : United Kingdom
Organisme : Versus Arthritis
ID : 20773
Pays : United Kingdom
Organisme : Versus Arthritis
ID : 22053
Pays : United Kingdom

Informations de copyright

© 2020 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.

Références

Cell Rep. 2020 Jun 30;31(13):107820
pubmed: 32610123
Nat Biotechnol. 2010 Oct;28(10):1045-8
pubmed: 20944595
Elife. 2016 Apr 21;5:e13941
pubmed: 27098840
J Invest Dermatol. 2013 Oct;133(10):2381-2389
pubmed: 23563201
Cell Rep. 2018 Jul 31;24(5):1163-1175
pubmed: 30067973
Immunol Rev. 2014 Sep;261(1):126-40
pubmed: 25123281
J Immunol. 2011 Jun 1;186(11):6368-77
pubmed: 21515796
Nucleic Acids Res. 2012 Nov;40(21):e168
pubmed: 22904091
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D659-63
pubmed: 16381953
Nat Immunol. 2011 Nov 13;13(1):86-94
pubmed: 22080921
Biochim Biophys Acta. 2015 Apr;1855(2):131-43
pubmed: 25641675
Sci Immunol. 2020 May 22;5(47):
pubmed: 32444476
PLoS Pathog. 2011 Jan 06;7(1):e1001246
pubmed: 21253574
Nat Immunol. 2012 Jul 01;13(8):770-7
pubmed: 22751139
Ann Rheum Dis. 2016 Aug;75(8):1534-40
pubmed: 26452539
Nat Commun. 2015 May 21;6:7146
pubmed: 25994336
FEBS J. 2019 May;286(9):1624-1637
pubmed: 30199605
Proc Natl Acad Sci U S A. 2011 May 10;108(19):7745-50
pubmed: 21508329
Nat Commun. 2017 Nov 15;8(1):1510
pubmed: 29142230
Nat Immunol. 2011 Mar;12(3):231-8
pubmed: 21240265
Nat Genet. 2011 Jul 10;43(8):761-7
pubmed: 21743469
J Cell Sci. 2007 Aug 1;120(Pt 15):2619-30
pubmed: 17646674
Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9362-7
pubmed: 19474294
Curr Opin Immunol. 2018 Apr;51:14-23
pubmed: 29278858
Mol Cell Proteomics. 2019 Mar 15;18(Suppl 1):S46-S58
pubmed: 30287546
Front Immunol. 2018 Nov 20;9:2622
pubmed: 30515152
EMBO J. 1999 Jun 1;18(11):3090-100
pubmed: 10357820
Mol Cell Biol. 2014 Mar;34(6):1158-69
pubmed: 24421391
Mol Cell. 2018 Jul 5;71(1):56-72.e4
pubmed: 30008319
Nat Rev Genet. 2009 Apr;10(4):252-63
pubmed: 19274049
Int J Mol Sci. 2017 May 11;18(5):
pubmed: 28492513
Nat Genet. 2013 Jul;45(7):730-8
pubmed: 23749187
Cell. 2009 Oct 30;139(3):610-22
pubmed: 19879846
Nature. 2020 Jan;577(7789):179-189
pubmed: 31915397
Front Immunol. 2019 Apr 08;10:739
pubmed: 31024565
Nat Rev Rheumatol. 2015 Oct;11(10):562
pubmed: 26369611
Front Immunol. 2019 May 17;10:1029
pubmed: 31156624
Transl Res. 2016 Jan;167(1):167-82
pubmed: 26207886
Clin Rheumatol. 2017 Feb;36(2):469-475
pubmed: 27761751
J Biol Chem. 2004 Oct 22;279(43):45194-207
pubmed: 15308637
Nucleic Acids Res. 2018 Jan 4;46(D1):D649-D655
pubmed: 29145629
Nat Commun. 2019 Jul 24;10(1):3306
pubmed: 31341159
Mediators Inflamm. 2013;2013:245804
pubmed: 24453413
Proteomics. 2015 Apr;15(7):1224-9
pubmed: 25515006
Immunity. 1999 Mar;10(3):345-55
pubmed: 10204490
Biochem Biophys Res Commun. 2011 Nov 18;415(2):342-7
pubmed: 22033400
Rheumatology (Oxford). 2012 Apr;51(4):619-26
pubmed: 22179739
Immunity. 2004 Jun;20(6):719-33
pubmed: 15189737
Immunity. 1998 Oct;9(4):543-53
pubmed: 9806640
Nat Genet. 2016 May;48(5):510-8
pubmed: 26974007

Auteurs

Matteo Vecellio (M)

NIHR Oxford Musculoskeletal Biomedical Research Unit, Botnar Research Centre, Nuffield Orthopaedic Centre, NIHR Oxford Comprehensive Biomedical Research Centre, University of Oxford, Oxford, UK.

Liye Chen (L)

NIHR Oxford Musculoskeletal Biomedical Research Unit, Botnar Research Centre, Nuffield Orthopaedic Centre, NIHR Oxford Comprehensive Biomedical Research Centre, University of Oxford, Oxford, UK.

Carla J Cohen (CJ)

NIHR Oxford Musculoskeletal Biomedical Research Unit, Botnar Research Centre, Nuffield Orthopaedic Centre, NIHR Oxford Comprehensive Biomedical Research Centre, University of Oxford, Oxford, UK.

Adrian Cortes (A)

John Radcliffe Hospital, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.

Yan Li (Y)

The First Affiliated Hospital of Xiamen University and Xiamen University School of Medicine, Xiamen, China.

Sarah Bonham (S)

Target Discovery Institute, University of Oxford, Oxford, UK.

Carlo Selmi (C)

IRCCS Humanitas Research Hospital, Milan, Italy.

Matthew A Brown (MA)

NIHR Guy's and St. Thomas' Biomedical Research Centre, London, UK, and University of Queensland, Brisbane, Queensland, Australia.

Roman Fischer (R)

Target Discovery Institute, University of Oxford, Oxford, UK.

Julian C Knight (JC)

Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.

B Paul Wordsworth (BP)

NIHR Oxford Musculoskeletal Biomedical Research Unit, Botnar Research Centre, Nuffield Orthopaedic Centre, NIHR Oxford Comprehensive Biomedical Research Centre, University of Oxford, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH